Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ImClone, Merck KGaA Revise Erbitux Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ImClone, Merck KGaA Revise Erbitux Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ImClone Systems and Merck KGaA have revised their licensing agreement for cancer drug Erbitux. Under the terms of the new agreement, Merck will sublicense certain intellectual property rights from ImClone related to the development of antibodies targeting a protein known as epidermal growth factor to Takeda Pharmaceutical Co.

Merck will pay ImClone $3.2 million when the agreements are executed and an additional $6.3 million upon ImClone’s written consent to the sublicense. Also, Merck has increased its royalty for all sales of Erbitux outside the U.S. and Canada, effective July 1.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters